The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review

Mingjie Yao, Leijie Wang, Patrick S Leung, Yanmei Li, Shuhong Liu, Lu Wang, Xiaodong Guo, Guangde Zhou, Ying Yan, Guiwen Guan, Xiangmei Chen, Christopher Bowlus, Tianhui Liu, Jidong Jia, M. Eric Gershwin, Xiong Ma, Jingmin Zhao, Fengmin Lu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There is significant void in establishing validated non-invasive surrogate biomarkers of liver fibrosis/cirrhosis in chronic liver diseases (CLD). Golgi protein 73 (GP73) has been suggested as a potential serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, significant background of cirrhosis could have accounted for the elevation of serum GP73 in HCC. In this study, we have taken advantage of a well-defined extensive cohort of 3044 patients with either compensated cirrhosis (n = 1247), decompensated cirrhosis (n = 841) or pre-cirrhotic CLD (n = 956) and our ability to quantify serum GP73 to define the potential of serum GP73 as a biomarker of liver cirrhosis/fibrosis in CLD. The diagnostic value of GP73 was compared with aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis index based on four factors (FIB-4) and liver stiffness measurement (LSM). Immunohistochemical analysis was performed to measure hepatic GP73 expression. Receiver operating characteristic curve analysis demonstrated that serum GP73 had a good diagnostic potential for compensated cirrhosis regardless of etiology. The diagnostic performance of GP73 is better than APRI, FIB-4 and similar with LSM, especially in patients with severe inflammation, steatosis and cholestasis. Notably, in patients of autoimmune liver diseases, non-alcoholic fatty liver disease and viral hepatitis, serum GP73 also exhibited diagnostic value for advanced fibrosis as well as cirrhosis. Furthermore, there is also a gradual increase in GP73 expression with disease progression from mild fibrosis to cirrhosis. In conclusion, GP73 is an effective and reliable serological marker for the diagnosis of advanced fibrosis and prediction of appearance of cirrhosis.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalClinical Reviews in Allergy and Immunology
DOIs
StateAccepted/In press - Nov 24 2017

Fingerprint

Liver Diseases
Fibrosis
Chronic Disease
Proteins
Blood Proteins
Liver Cirrhosis
Biomarkers
Hepatocellular Carcinoma
Liver
Blood Platelets
Cholestasis
Aspartate Aminotransferases
Transaminases
ROC Curve
Hepatitis
Autoimmune Diseases
Disease Progression
Inflammation

Keywords

  • APRI
  • Chronic liver disease
  • FIB-4
  • Fibrosis
  • Liver stiffness

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases : Experimental Data and Literature Review. / Yao, Mingjie; Wang, Leijie; Leung, Patrick S; Li, Yanmei; Liu, Shuhong; Wang, Lu; Guo, Xiaodong; Zhou, Guangde; Yan, Ying; Guan, Guiwen; Chen, Xiangmei; Bowlus, Christopher; Liu, Tianhui; Jia, Jidong; Gershwin, M. Eric; Ma, Xiong; Zhao, Jingmin; Lu, Fengmin.

In: Clinical Reviews in Allergy and Immunology, 24.11.2017, p. 1-13.

Research output: Contribution to journalArticle

Yao, Mingjie ; Wang, Leijie ; Leung, Patrick S ; Li, Yanmei ; Liu, Shuhong ; Wang, Lu ; Guo, Xiaodong ; Zhou, Guangde ; Yan, Ying ; Guan, Guiwen ; Chen, Xiangmei ; Bowlus, Christopher ; Liu, Tianhui ; Jia, Jidong ; Gershwin, M. Eric ; Ma, Xiong ; Zhao, Jingmin ; Lu, Fengmin. / The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases : Experimental Data and Literature Review. In: Clinical Reviews in Allergy and Immunology. 2017 ; pp. 1-13.
@article{4382138353ba43db8eb362f997f3371e,
title = "The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review",
abstract = "There is significant void in establishing validated non-invasive surrogate biomarkers of liver fibrosis/cirrhosis in chronic liver diseases (CLD). Golgi protein 73 (GP73) has been suggested as a potential serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, significant background of cirrhosis could have accounted for the elevation of serum GP73 in HCC. In this study, we have taken advantage of a well-defined extensive cohort of 3044 patients with either compensated cirrhosis (n = 1247), decompensated cirrhosis (n = 841) or pre-cirrhotic CLD (n = 956) and our ability to quantify serum GP73 to define the potential of serum GP73 as a biomarker of liver cirrhosis/fibrosis in CLD. The diagnostic value of GP73 was compared with aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis index based on four factors (FIB-4) and liver stiffness measurement (LSM). Immunohistochemical analysis was performed to measure hepatic GP73 expression. Receiver operating characteristic curve analysis demonstrated that serum GP73 had a good diagnostic potential for compensated cirrhosis regardless of etiology. The diagnostic performance of GP73 is better than APRI, FIB-4 and similar with LSM, especially in patients with severe inflammation, steatosis and cholestasis. Notably, in patients of autoimmune liver diseases, non-alcoholic fatty liver disease and viral hepatitis, serum GP73 also exhibited diagnostic value for advanced fibrosis as well as cirrhosis. Furthermore, there is also a gradual increase in GP73 expression with disease progression from mild fibrosis to cirrhosis. In conclusion, GP73 is an effective and reliable serological marker for the diagnosis of advanced fibrosis and prediction of appearance of cirrhosis.",
keywords = "APRI, Chronic liver disease, FIB-4, Fibrosis, Liver stiffness",
author = "Mingjie Yao and Leijie Wang and Leung, {Patrick S} and Yanmei Li and Shuhong Liu and Lu Wang and Xiaodong Guo and Guangde Zhou and Ying Yan and Guiwen Guan and Xiangmei Chen and Christopher Bowlus and Tianhui Liu and Jidong Jia and Gershwin, {M. Eric} and Xiong Ma and Jingmin Zhao and Fengmin Lu",
year = "2017",
month = "11",
day = "24",
doi = "10.1007/s12016-017-8655-y",
language = "English (US)",
pages = "1--13",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",

}

TY - JOUR

T1 - The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases

T2 - Experimental Data and Literature Review

AU - Yao, Mingjie

AU - Wang, Leijie

AU - Leung, Patrick S

AU - Li, Yanmei

AU - Liu, Shuhong

AU - Wang, Lu

AU - Guo, Xiaodong

AU - Zhou, Guangde

AU - Yan, Ying

AU - Guan, Guiwen

AU - Chen, Xiangmei

AU - Bowlus, Christopher

AU - Liu, Tianhui

AU - Jia, Jidong

AU - Gershwin, M. Eric

AU - Ma, Xiong

AU - Zhao, Jingmin

AU - Lu, Fengmin

PY - 2017/11/24

Y1 - 2017/11/24

N2 - There is significant void in establishing validated non-invasive surrogate biomarkers of liver fibrosis/cirrhosis in chronic liver diseases (CLD). Golgi protein 73 (GP73) has been suggested as a potential serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, significant background of cirrhosis could have accounted for the elevation of serum GP73 in HCC. In this study, we have taken advantage of a well-defined extensive cohort of 3044 patients with either compensated cirrhosis (n = 1247), decompensated cirrhosis (n = 841) or pre-cirrhotic CLD (n = 956) and our ability to quantify serum GP73 to define the potential of serum GP73 as a biomarker of liver cirrhosis/fibrosis in CLD. The diagnostic value of GP73 was compared with aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis index based on four factors (FIB-4) and liver stiffness measurement (LSM). Immunohistochemical analysis was performed to measure hepatic GP73 expression. Receiver operating characteristic curve analysis demonstrated that serum GP73 had a good diagnostic potential for compensated cirrhosis regardless of etiology. The diagnostic performance of GP73 is better than APRI, FIB-4 and similar with LSM, especially in patients with severe inflammation, steatosis and cholestasis. Notably, in patients of autoimmune liver diseases, non-alcoholic fatty liver disease and viral hepatitis, serum GP73 also exhibited diagnostic value for advanced fibrosis as well as cirrhosis. Furthermore, there is also a gradual increase in GP73 expression with disease progression from mild fibrosis to cirrhosis. In conclusion, GP73 is an effective and reliable serological marker for the diagnosis of advanced fibrosis and prediction of appearance of cirrhosis.

AB - There is significant void in establishing validated non-invasive surrogate biomarkers of liver fibrosis/cirrhosis in chronic liver diseases (CLD). Golgi protein 73 (GP73) has been suggested as a potential serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, significant background of cirrhosis could have accounted for the elevation of serum GP73 in HCC. In this study, we have taken advantage of a well-defined extensive cohort of 3044 patients with either compensated cirrhosis (n = 1247), decompensated cirrhosis (n = 841) or pre-cirrhotic CLD (n = 956) and our ability to quantify serum GP73 to define the potential of serum GP73 as a biomarker of liver cirrhosis/fibrosis in CLD. The diagnostic value of GP73 was compared with aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis index based on four factors (FIB-4) and liver stiffness measurement (LSM). Immunohistochemical analysis was performed to measure hepatic GP73 expression. Receiver operating characteristic curve analysis demonstrated that serum GP73 had a good diagnostic potential for compensated cirrhosis regardless of etiology. The diagnostic performance of GP73 is better than APRI, FIB-4 and similar with LSM, especially in patients with severe inflammation, steatosis and cholestasis. Notably, in patients of autoimmune liver diseases, non-alcoholic fatty liver disease and viral hepatitis, serum GP73 also exhibited diagnostic value for advanced fibrosis as well as cirrhosis. Furthermore, there is also a gradual increase in GP73 expression with disease progression from mild fibrosis to cirrhosis. In conclusion, GP73 is an effective and reliable serological marker for the diagnosis of advanced fibrosis and prediction of appearance of cirrhosis.

KW - APRI

KW - Chronic liver disease

KW - FIB-4

KW - Fibrosis

KW - Liver stiffness

UR - http://www.scopus.com/inward/record.url?scp=85038384635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038384635&partnerID=8YFLogxK

U2 - 10.1007/s12016-017-8655-y

DO - 10.1007/s12016-017-8655-y

M3 - Article

C2 - 29256057

AN - SCOPUS:85038384635

SP - 1

EP - 13

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

ER -